Recent studies have shown that immune checkpoint inhibitors (ICIs) offer survival benefits for patients with HER2-negative advanced G/GEJ adenocarcinoma (Kang et al., 2022; Rha et al., 2023; Xu et al., 2023). This evidence concerns the gene ERBB2 and adenocarcinoma.